Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ram

Showing results (191-200 of 24,158) with videos related to

Pageof 2,416
Sort By:
ACS Medicinal Chemistry Letters|August 20, 2025
Novel Heterocyclic Compounds as 5‑HT2C Agonists for Treating Depression, Drug Addiction, Alcoholism, PTSD and Neuropathic PainRam W Sabnis
ACS Medicinal Chemistry Letters|August 20, 2025
Novel Compounds for Treating Huntington's DiseaseRam W Sabnis
ACS Medicinal Chemistry Letters|August 20, 2025
Novel Compounds as 5‑HT2A Agonists for Treating Mental Illness or CNS DisordersRam W Sabnis
ACS Medicinal Chemistry Letters|August 20, 2025
Novel Non-hallucinogenic Neurite Growth Compounds as 5‑HT2A Agonists for Treating Stress-Related Disorders, Namely Depression, Anxiety, and PTSDRam W Sabnis
ACS Medicinal Chemistry Letters|August 20, 2025
Novel Compounds as Emopamil-Binding Protein Inhibitors for Treating Multiple SclerosisRam W Sabnis
ACS Medicinal Chemistry Letters|February 18, 2026
Novel Cyclopentapyrrole Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, namely, Narcolepsy and HypersomniaRam W Sabnis
ACS Medicinal Chemistry Letters|February 18, 2026
Novel Compounds as ARNT Degraders for Treating Cancer, in Particular, Hematological CancerRam W Sabnis
ACS Medicinal Chemistry Letters|February 18, 2026
Novel Compounds as PKC-Theta Inhibitors for Treating Autoimmune or Inflammatory DiseasesRam W Sabnis
ACS Medicinal Chemistry Letters|February 18, 2026
Novel Compounds as CX3CR1Modulators for Treating Cardiovascular DiseasesRam W Sabnis
ACS Medicinal Chemistry Letters|February 19, 2025
Novel Carbocyclic Phenylpyrrolidinone Urea Compounds as FPR2 Agonists for Treating Atherosclerosis and Heart FailureRam W Sabnis
Pageof 2,416

Showing results (191-200 of 24,158) with videos related to

Sort By:
Pageof 2,416
ACS Medicinal Chemistry Letters|August 20, 2025
Novel Heterocyclic Compounds as 5‑HT2C Agonists for Treating Depression, Drug Addiction, Alcoholism, PTSD and Neuropathic PainRam W Sabnis
ACS Medicinal Chemistry Letters|August 20, 2025
Novel Compounds for Treating Huntington's DiseaseRam W Sabnis
ACS Medicinal Chemistry Letters|August 20, 2025
Novel Compounds as 5‑HT2A Agonists for Treating Mental Illness or CNS DisordersRam W Sabnis
ACS Medicinal Chemistry Letters|August 20, 2025
Novel Non-hallucinogenic Neurite Growth Compounds as 5‑HT2A Agonists for Treating Stress-Related Disorders, Namely Depression, Anxiety, and PTSDRam W Sabnis
ACS Medicinal Chemistry Letters|August 20, 2025
Novel Compounds as Emopamil-Binding Protein Inhibitors for Treating Multiple SclerosisRam W Sabnis
ACS Medicinal Chemistry Letters|February 18, 2026
Novel Cyclopentapyrrole Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, namely, Narcolepsy and HypersomniaRam W Sabnis
ACS Medicinal Chemistry Letters|February 18, 2026
Novel Compounds as ARNT Degraders for Treating Cancer, in Particular, Hematological CancerRam W Sabnis
ACS Medicinal Chemistry Letters|February 18, 2026
Novel Compounds as PKC-Theta Inhibitors for Treating Autoimmune or Inflammatory DiseasesRam W Sabnis
ACS Medicinal Chemistry Letters|February 18, 2026
Novel Compounds as CX3CR1Modulators for Treating Cardiovascular DiseasesRam W Sabnis
ACS Medicinal Chemistry Letters|February 19, 2025
Novel Carbocyclic Phenylpyrrolidinone Urea Compounds as FPR2 Agonists for Treating Atherosclerosis and Heart FailureRam W Sabnis
Pageof 2,416